1998
DOI: 10.1177/096120339800700224
|View full text |Cite
|
Sign up to set email alerts
|

Anti β2-glycoprotein I antibodies: Clinical significance

Abstract: The introduction of anticardiolipin antibody (aCL) assay, described in 1983, was able to focus much attention on the study of patients suffering from thrombosis, repeated fetal loss and thrombocytopenia, and allowing the identification of the so called antiphospholipid syndrome (APS). The identification of β2 glycoprotein I (β22GPI) as an essential component of the antigenic complex recognized by aCL suggested that this molecule could be a direct target of the antibody response. Since then, different groups ha… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
7
1
2

Year Published

2001
2001
2011
2011

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 15 publications
(10 citation statements)
references
References 22 publications
0
7
1
2
Order By: Relevance
“…POAG patients have significantly increased b2AGP concentrations, and the number of patients with elevated concentrations is significantly increased. The identification of b2AGP as an essential component of the antigenic complex recognized by ACL suggested that this molecule could be a direct target of the antibody response [15]. Our findings contrast with the results of Tsakiris et al [16] who found comparable b2AGP levels in NTG patients, chronic POAG patients and controls.…”
Section: Discussioncontrasting
confidence: 99%
“…POAG patients have significantly increased b2AGP concentrations, and the number of patients with elevated concentrations is significantly increased. The identification of b2AGP as an essential component of the antigenic complex recognized by ACL suggested that this molecule could be a direct target of the antibody response [15]. Our findings contrast with the results of Tsakiris et al [16] who found comparable b2AGP levels in NTG patients, chronic POAG patients and controls.…”
Section: Discussioncontrasting
confidence: 99%
“…This is the first study to report the aPL isotype distribution of aβ2‐GPI antibody subtypes IgG, IgM and IgA in an APS cohort. Although aβ2‐GPI is not included in the diagnostic criteria of APS, it has been realized in recent years that aβ2‐GPI confers an overall better specificity in the clinical evaluation of patients with APS and a higher positive predictive value 11,12 . There is also a certain subset of seronegative APS patients who are only positive for aβ2‐GPI 13 .…”
Section: Discussionmentioning
confidence: 99%
“…Both in vitro and in vivo experimental models are highly suggestive of aPL having a direct pathogenic role in APS rather than simply being serologic markers for the disorder (4, 19). Several studies have demonstrated that the binding of pathogenic aPL to phospholipids is closely related to antibody reactivity against the β 2 GPI molecule (16, 20, 21). Not only have studies shown that anti‐β 2 GPI is a significant clinical indicator of APS (18, 22, 23), but it has also been suggested that anti‐β 2 GPI has a direct pathogenic role in APS by interfering with hemostatic reactions and with different cell types involved in both the coagulation cascade and placental implantation (4).…”
Section: Discussionmentioning
confidence: 99%